CCK, PYY and PP: The control of energy balance

Handbook of Experimental Pharmacology

Volumn 209, Issue , 2012, Pages 209-230

  Simpson, K ^a   Parker, J ^a   Plumer, J ^a   Bloom, S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Brainstem; Cholecystokinin; Gut; Hypothalamus; Obesity; Pancreatic polypeptide; Peptide YY; Vagal afferents

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; FATTY ACID; GI 181771; HORMONE RECEPTOR STIMULATING AGENT; LEPTIN; NEUROPEPTIDE Y2 RECEPTOR; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO; NEUROPEPTIDE RECEPTOR;

ANOREXIA; APPETITE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN STEM RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENERGY BALANCE; ENERGY CONSUMPTION; GASTROINTESTINAL SYMPTOM; HORMONE RELEASE; HUMAN; NERVE CONDUCTION; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; RECEPTOR BLOCKING; SATIETY; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; BRAIN; ENERGY METABOLISM; FOOD INTAKE; GASTROINTESTINAL TRACT; HOMEOSTASIS; INNERVATION; METABOLISM; PSYCHOPHYSIOLOGY; REVIEW;

ANIMALS; APPETITE REGULATION; BRAIN; CHOLECYSTOKININ; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; PANCREATIC POLYPEPTIDE; PEPTIDE YY; RECEPTORS, NEUROPEPTIDE; SATIETY RESPONSE; SIGNAL TRANSDUCTION;

EID: 84856353661     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-24716-3_9     Document Type: Article

References (159)

1. 7TM Pharma2007) Results from a Phase I/II clinical study with the drug candidate Obinepitide for the treatment of obesity. Press release 28th Nov 2007. http://www.7tm.com/News/ News-Archive.aspx?MNews&PID45&NewsID9
2. 7TM Pharma2011) TM30339. Metabolic disorders http://www.7tm.com/R-D/ Metabolic-Disorders/TM30339.aspx
3. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA et al2005a) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043(1-2):139-144 (Pubitemid 40603381)
4. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR et al2005b) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044(1):127-131 (Pubitemid 40616060)
5. Acuna-Goycolea C, van den Pol AN2005) Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25(45):10510-10519 (Pubitemid 41628453)
6. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ1976) Distribution and release of human pancreatic polypeptide. Gut 17(12):940-944 (Pubitemid 8027537)
7. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 895):1070-1077 (Pubitemid 16231572)
8. Andrews PL1986) Vagal afferent innervation of the gastrointestinal tract. Prog Brain Res 67:65-86
9. Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT et al2008) Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol 590(1-3):224-232
10. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 2012):1445-1448 (Pubitemid 30069890)
11. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, FujimiyaMet al2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 1245):1325-1336 (Pubitemid 36531807)
12. Ashby D, Bloom SR2007) Recent progress in PYY research - an update report for 8th NPY meeting. Peptides 28(2):198-202 (Pubitemid 46178463)
13. Bado A, Rodriguez M, Lewin MJ, Martinez J, Dubrasquet M1988) Cholecystokinin suppresses food intake in cats: structure-activity characterization. Pharmacol Biochem Behav 312):297-303 (Pubitemid 19275144)
14. Baird JP, Travers JB, Travers SP2001) Parametric analysis of gastric distension responses in the parabrachial nucleus. Am J Physiol Regul Integr Comp Physiol 281(5):R1568-R1580
15. Ballantyne GH, Goldenring JR, Savoca PE, Kranz HK, Adrian TE, Bilchik AJ et al1993) Cyclic AMP-mediated release of peptide YYPYY) from the isolated perfused rabbit distal colon. Regul Pept 47(2):117-126
16. Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y1997) Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A 94(19):10455-10460 (Pubitemid 27407063)
17. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL et al2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418(6898):650-654
18. Batterham RL, Cohen MA, Ellis SM, le Roux CW, Withers DJ, Frost GS et al2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349(10):941-948 (Pubitemid 37064767)
19. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H et al2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 43):223-233 (Pubitemid 44307976)
20. Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ et al2007) PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450(7166):106-109 (Pubitemid 350070563)
21. Bellmann-Sickert K, Elling CE, Madsen AN, Little PB, Lundgren K, Gerlach LO et al2011) Long-acting lipidated analog of human pancreatic polypeptide is slowly released into circulation. J Med Chem 54(8):2658-2667
22. Berglund MM, Hipskind PA, Gehlert DR2003) Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol MedMaywood ) 2283):217-244 (Pubitemid 36314489)
23. Bi S, Moran TH2002) Actions of CCK in the controls of food intake and body weight: lessons from the CCK-A receptor deficient OLETF rat. Neuropeptides 36(2-3):171-181
24. Bi S, Scott KA, Kopin AS, Moran TH2004) Differential roles for cholecystokinin a receptors in energy balance in rats and mice. Endocrinology 145(8):3873-3880 (Pubitemid 39037576)
25. Blackshaw LA, Grundy D1990) Effects of cholecystokininCCK-8) on two classes of gastroduodenal vagal afferent fibre. J Auton Nerv Syst 31(3):191-201
26. Blevins JE, Stanley BG, Reidelberger RD2000) Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 860(1-2):1-10 (Pubitemid 30155832)
27. Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y et al2005) PYY3-36 as an anti-obesity drug target. Obes Rev 6(4):307-322 (Pubitemid 41578600)
28. Broberger C, Landry M, Wong H, Walsh JN, Hokfelt T1997) Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide- Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 666):393-408 (Pubitemid 27500899)
29. Browning KN, Travagli RA2009) Modulation of inhibitory neurotransmission in brainstem vagal circuits by NPY and PYY is controlled by cAMP levels. Neurogastroenterol Motil 2112):1309-e126
30. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ2004) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24(11):2708-2715 (Pubitemid 38380947)
31. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ2006) Feeding-dependent depression of melanin-concentrating hormone and melanin-concentrating hormone receptor-1 expression in vagal afferent neurones. Neuroscience 137(4):1405-1415 (Pubitemid 43133164)
32. Burdyga G, de LG, Raybould HE, Morris R, Dimaline R, Varro A et al2008) Cholecystokinin regulates expression of Y2 receptors in vagal afferent neurons serving the stomach. J Neurosci 28(45):11583-11592
33. Cawston EE, Miller LJ2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol 159(5):1009-1021
34. Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR et al2004) Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A 101(13):4695-4700 (Pubitemid 38437473)
35. Chaudhri OB, Wynne K, Bloom SR2008) Can gut hormones control appetite and prevent obesity? Diabetes Care 31(Suppl 2):S284-S289
36. Chen DY, Deutsch JA, Gonzalez MF, Gu Y1993) The induction and suppression of c-fos expression in the rat brain by cholecystokinin and its antagonist L364,718. Neurosci Lett 149(1):91-94 (Pubitemid 23022138)
37. Clerc P, Coll Constans MG, Lulka H, Broussaud S, Guigne C, Leung-Theung-Long S et al2007) Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. Endocrinology 1483):1039-1049
38. Conigrave AD, Quinn SJ, Brown EM2000) L-Amino acid sensing by the extracellular Ca2+- sensing receptor. Proc Natl Acad Sci U S A 97(9):4814-4819 (Pubitemid 30238640)
39. Corwin RL, Gibbs J, Smith GP1991) Increased food intake after type A but not type B cholecystokinin receptor blockade. Physiol Behav 50(1):255-258
40. Crawley JN, Kiss JZ1985) Paraventricular nucleus lesions abolish the inhibition of feeding induced by systemic cholecystokinin. Peptides 6(5):927-935 (Pubitemid 16170982)
41. Crawley JN, Schwaber JS1984) Abolition of the behavioral effects of cholecystokinin following bilateral radiofrequency lesions of the parvocellular subdivision of the nucleus tractus solitarius. Brain Res 295(2):289-299 (Pubitemid 14161037)
42. Crawley JN, Kiss JZ, Mezey E1984) Bilateral midbrain transections block the behavioral effects of cholecystokinin on feeding and exploration in rats. Brain Res 322(2):316-321 (Pubitemid 15209389)
43. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, Heyer D2002) Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept 106(1-3):47-54 (Pubitemid 34607337)
44. Daughters RS, Hofbauer RD, Grossman AW, Marshall AM, Brown EM, Hartman BK et al2001) Ondansetron attenuates CCK induced satiety and c-fos labeling in the dorsal medulla. Peptides 22(8):1331-1338 (Pubitemid 32703705)
45. Day HE, McKnight AT, Poat JA, Hughes J1994) Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology 33(6):719-727
46. De Lartigue G, Dimaline R, Varro A, Dockray GJ2007) Cocaine- and amphetamine-regulated transcript: stimulation of expression in rat vagal afferent neurons by cholecystokinin and suppression by ghrelin. J Neurosci 27(11):2876-2882 (Pubitemid 46438967)
47. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F et al1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 3842-3):R3-R5 (Pubitemid 30006963)
48. Eberlein GA, Eysselein VE, Goebell H1988) Cholecystokinin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine. Peptides 9(5):993-998 (Pubitemid 19265181)
49. Edwards GL, Ladenheim EE, Ritter RC1986) Dorsomedial hindbrain participation in cholecystokinin- induced satiety. Am J Physiol 251(5 Pt 2):R971-R977
50. Emisphere Technologies2009) Emisphere technologies reports encouraging data from independent clinical study assessing the effects of oral GLP-1 and PYY3-36, combined with Eligen(R) technology on appetite suppression. Press release 26th May 2009. http://ir.emisphere.com/ releasedetail.cfm? ReleaseID385806
51. Fernandez-Fernandez R, Aguilar E, Tena-Sempere M, Pinilla L2005) Effects of polypeptide YY3-36) upon luteinizing hormone-releasing hormone and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies. Endocrinology 146(3):1403-1410 (Pubitemid 40289329)
52. Funakoshi A2000) Gene structure of human cholecystokininCCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett 4662-3):264
53. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK et al2007) Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 925):1754-1757 (Pubitemid 46997183)
54. Gao F, Sexton PM, Christopoulos A, Miller LJ2008) Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett 18(15):4401-4404
55. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR1983) Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57(3):488-495 (Pubitemid 13005511)
56. Gibb BJ2010) Wellcome Trust. PP 1420: a breakthrough in appetite suppression. 6th Oct 2010. http://wellcometrust.wordpress.com/2010/10/06/pp1420/
57. Gibbs J, Young RC, Smith GP1973) Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84(3):488-495
58. Grandt D, Teyssen S, Schimiczek M, Reeve JR Jr, Feth F, Rascher W et al1992) Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Commun 186(3):1299-1306 (Pubitemid 23189465)
59. Guo Y, Ma L, Enriori PJ, Koska J, Franks PW, Brookshire T et al2006) Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. ObesitySilver Spring) 14(9):1562-1570 (Pubitemid 46214823)
60. Gustafson EL, Smith KE, Durkin MM, Walker MW, Gerald C, Weinshank R et al1997) Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res Mol Brain Res 46(1-2):223-235 (Pubitemid 27218305)
61. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller LJ1996) Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas 13(2):130-139 (Pubitemid 26266223)
62. Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ2006) Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem 49(3):850-863 (Pubitemid 43221633)
63. Hajnal A, Takenouchi K, Norgren R1999) Effect of intraduodenal lipid on parabrachial gustatory coding in awake rats. J Neurosci 19(16):7182-7190 (Pubitemid 29380142)
64. Halatchev IG, Cone RD2005) Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1(3):159-168 (Pubitemid 43960603)
65. Halatchev IG, Ellacott KL, Fan W, Cone RD2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145(6):2585-2590 (Pubitemid 38686200)
66. Hankir MK, Parkinson JR, Minnion JS, Addison M, Bloom SR, Bell JD2011) PYY(3-36) and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese enhanced MRI. J Neuroendocrinol 23(4):371-380
67. Helou N, Obeid O, Azar ST, Hwalla N2008) Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab 523):188-195 (Pubitemid 351990888)
68. Hill DR, Campbell NJ, Shaw TM, Woodruff GN1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7(9):2967-2976
69. Hill DR, Shaw TM, Graham W, Woodruff GN1990) Autoradiographical detection of cholecystokinin- A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329. J Neurosci 10(4):1070-1081
70. Hipskind PA, Lobb KL, Nixon JA, Britton TC, Bruns RF, Catlow J et al1997) Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J Med Chem 40(23):3712-3714 (Pubitemid 127744506)
71. Hirosue Y, Inui A, Teranishi A, Miura M, Nakajima M, Okita M et al1993) Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice. Am J Physiol 265(3 Pt 2):R481-R486 (Pubitemid 23294992)
72. Hort Y, Baker E, Sutherland GR, Shine J, Herzog H1995) Gene duplication of the human peptide YY genePYY) generated the pancreatic polypeptide genePPY) on chromosome 17q21.1. Genomics 26(1):77-83
73. Innis RB, Correa FM, Uhl GR, Schneider B, Snyder SH1979) Cholecystokinin octapeptide-like immunoreactivity: histochemical localization in rat brain. Proc Natl Acad Sci U S A 761):521-525 (Pubitemid 9106661)
74. Johns CE, Newton JL, Westley BR, May FE2006) Human pancreatic polypeptide has a marked diurnal rhythm that is affected by ageing and is associated with the gastric TFF2 circadian rhythm. Peptides 27(6):1341-1348 (Pubitemid 43767002)
75. Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K et al2008) Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83(2):281-287
76. Jorde R, Burhol PG1984) Fasting and postprandial plasma pancreatic polypeptidePP) levels in obesity. Int J Obes 8(5):393-397 (Pubitemid 15215946)
77. Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T et al2006) Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl- carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl- ethy l)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J Pharmacol Exp Ther 3172):562-570
78. Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T et al1999) The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 266(1):88-91 (Pubitemid 30028772)
79. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34(2):154-160 (Pubitemid 11186304)
80. Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K et al2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 1465):2369-2375 (Pubitemid 40577525)
81. Kojima S, Ueno N, Asakawa A, Sagiyama K, Naruo T, Mizuno S et al2007) A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 28(2):459-463 (Pubitemid 46176251)
82. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F et al1999) The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103(3):383-391 (Pubitemid 29069988)
83. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L et al2006) Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. ObesitySilver Spring) 14(9):1553-1561 (Pubitemid 46214822)
84. Lassmann V, Vague P, Vialettes B, Simon MC1980) Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29(6):428-430 (Pubitemid 11018461)
85. le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR2008) Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 45(Pt 1):93-95 (Pubitemid 351724622)
86. Li BH, Rowland NE1995) Effects of vagotomy on cholecystokinin- and dexfenfluramineinduced Fos-like immunoreactivity in the rat brain. Brain Res Bull 37(6):589-593
87. Li Y, Wu X, Zhou S, Owyang C2011) Low-affinity CCK-A receptors are coexpressed with leptin receptors in rat nodose ganglia: implications for leptin as a regulator of short-term satiety. Am J Physiol Gastrointest Liver Physiol 300(2):G217-G227
88. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA1985) Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75(4):1144-1152 (Pubitemid 15087139)
89. Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, Macia L et al2009) Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One 4(12):e8488
90. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ et al2010) The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140(3):903-912
91. Lumb KJ, DeCarr LB, Milardo LF, Mays MR, Buckholz TM, Fisk SE et al2007) Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J Med Chem 50(9):2264-2268 (Pubitemid 46683081)
92. Marino CR, Leach SD, Schaefer JF, Miller LJ, Gorelick FS1993) Characterization of cAMPdependent protein kinase activation by CCK in rat pancreas. FEBS Lett 316(1):48-52 (Pubitemid 23029205)
93. McFadden DW, Rudnicki M, Kuvshinoff B, Fischer JE1992) Postprandial peptide YY release is mediated by cholecystokinin. Surg Gynecol Obstet 175(2):145-150
94. McLaughlin J, Grazia LM, Jones MN, D'Amato M, Dockray GJ, Thompson DG1999) Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 116(1):46-53 (Pubitemid 29013492)
95. MDRNA2008) MDRNA announces phase 2 trial of PYY(3-36) does not meet weight loss endpoint. MDRNA Press release 31st July 2008. http://phx.corporate- ir.net/phoenix.zhtml? c83674&pirol- newsArticle&ID1182214&highlightPYY%20nasal%20spray
96. Mentlein R, Dahms P, Grandt D, Kruger R1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49(2):133-144
97. Mercer LD, Beart PM1997) Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor. Neurosci Lett 225(2):97-100 (Pubitemid 27166110)
98. Meyer JH, Kelly GA, Spingola LJ, Jones RS1976) Canine gut receptors mediating pancreatic responses to luminal L-amino acids. Am J Physiol 231(3):669-677
99. Miller LJ, Gao F2008) Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther 119(1):83-95
100. Moran TH2008) Unraveling the obesity of OLETF rats. Physiol Behav 94(1):71-78 (Pubitemid 351503584)
101. Moran TH, McHugh PR1982) Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 242(5):R491-R497 (Pubitemid 12099150)
102. Moran TH, Robinson PH, Goldrich MS, McHugh PR1986) Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362(1):175-179 (Pubitemid 16185437)
103. Moran TH, Smith GP, Hostetler AM, McHugh PR1987) Transport of cholecystokininCCK) binding sites in subdiaphragmatic vagal branches. Brain Res 415(1):149-152 (Pubitemid 17097385)
104. Mutt V, Jorpes E1971) Hormonal polypeptides of the upper intestine. Biochem J 125(3):57P-58P
105. Ondetti MA, Pluscec J, Sabo EF, Sheehan JT, Williams N1970) Synthesis of cholecystokininpancreozymin. I. The C-terminal dodecapeptide. J Am Chem Soc 92(1):195-199
106. Ozcelebi F1995) Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem 270(7):3435
107. Parker RM, Herzog H1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 11(4):1431-1448 (Pubitemid 29142202)
108. Parrott RF1993) Peripheral and central effects of CCK receptor agonists on operant feeding in pigs. Physiol Behav 53(2):367-372 (Pubitemid 23048344)
109. Passaro E Jr, Debas H, Oldendorf W, Yamada T1982) Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res 241(2):335-340
110. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T et al2007) Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92(2):583-588
111. Pinilla L, Fernandez-Fernandez R, Roa J, Castellano JM, Tena-Sempere M, Aguilar E2007) Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat. Am J Physiol Endocrinol Metab 293(5):E1385-E1392 (Pubitemid 350106608)
112. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP1982) C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 29(4):627-630 (Pubitemid 13220507)
113. Pizzi DA, Leslie CP, Mazzali A, Seri C, Biagetti M, Bentley J et al2010) Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists. Bioorg Med Chem Lett 20(23):7120-7123
114. Pohl M, Silvente-Poirot S, Pisegna JR, Tarasova NI, Wank SA1997) Ligand-induced internalization of cholecystokinin receptors. Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type A receptor. J Biol Chem 272(29):18179-18184 (Pubitemid 27306404)
115. Rao RV, Roettger BF, Hadac EM, Miller LJ1997) Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol 51(2):185-192 (Pubitemid 27074138)
116. Regard JB, Sato IT, Coughlin SR2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135(3):561-571
117. Reidelberger RD1992) Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats. Am J Physiol 263(6 Pt 2):R1354-R1358 (Pubitemid 23019137)
118. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M et al1994) The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271(2-3):R11-R13
119. Rueeger H, Rigollier P, Yamaguchi Y, Schmidlin T, Schilling W, Criscione L et al2000) Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett 10(11):1175-1179 (Pubitemid 30345085)
120. Sainsbury A, Shi YC, Zhang L, Aljanova A, Lin Z, Nguyen AD et al2010) Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways. Neuropeptides 44(3):261-268
121. Sankaran H, Goldfine ID, Bailey A, Licko V, Williams JA1982) Relationship of cholecystokinin receptor binding to regulation of biological functions in pancreatic acini. Am J Physiol 242(3): G250-G257 (Pubitemid 12046255)
122. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR1987) Effects of peptide YYPYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28(2):166-170 (Pubitemid 17027386)
123. Sayegh AI, Ritter RC2000) Vagus nerve participates in CCK-induced Fos expression in hindbrain but not myenteric plexus. Brain Res 878(1-2):155-162
124. Schwartz GJ2000) The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 16(10):866-873
125. Schwartz GJ, Salorio CF, Skoglund C, Moran TH1999) Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. Am J Physiol 276(6 Pt 2): R1623-R1629 (Pubitemid 29323525)
126. Simmons RD, Kaiser FC, Pierson ME, Rosamond JR1998) ARL 15849: a selective CCK-A agonist with anorectic activity in the rat and dog. Pharmacol Biochem Behav 59(2):439-444 (Pubitemid 28072740)
127. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A2007) Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292(4):E1062-E1068 (Pubitemid 46536505)
128. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ1981) Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213(4511):1036-1037
129. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL2005) Peripheral exendin-4 and peptide YY3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146(9):3748-3756 (Pubitemid 41175742)
130. Tanaka T, Katsuma S, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G2008) Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol 377(4-6):523-527
131. Taylor IL, Impicciatore M, Carter DC, Walsh JH1978) Effect of atropine and vagotomy on pancreatic polypeptide response to a meal in dogs. Am J Physiol 235(4):E443-E447 (Pubitemid 9163016)
132. Ter Horst GJ, Luiten PG, Kuipers F1984) Descending pathways from hypothalamus to dorsal motor vagus and ambiguus nuclei in the rat. J Auton Nerv Syst 11(1):59-75 (Pubitemid 14091295)
133. Ter Horst GJ, de Boer P, Luiten PG, van Willigen JD1989) Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat. Neuroscience 31(3):785-797 (Pubitemid 20032965)
134. Thompson JC, Fender HR, Ramus NI, Villar HV, Rayford PL1975) Cholecystokinin metabolism in man and dogs. Ann Surg 182(4):496-504
135. Toth PT, Bindokas VP, Bleakman D, Colmers WF, Miller RJ1993) Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve terminals. Nature 364(6438):635-639 (Pubitemid 23274721)
136. Tough IR, Forbes S, Tolhurst R, Ellis M, Herzog H, Bornstein JC et al2011) Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y(1) and Y(2) receptors. Br J Pharmacol 164(2b):471-484
137. Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S et al2004) Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430(6996):1
138. Tunstall-Pedoe H2005) Preventing chronic diseases. A vital investment. WHO Global Report, Geneva
139. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M et al1999) Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 1176):1427-1432
140. Uhe AM, Szmukler GI, Collier GR, Hansky J, O'Dea K, Young GP1992) Potential regulators of feeding behavior in anorexia nervosa. Am J Clin Nutr 55(1):28-32
141. Utz AL, Lawson EA, Misra M, Mickley D, Gleysteen S, Herzog DB et al2008) Peptide YYPYY) levels and bone mineral densityBMD) in women with anorexia nervosa. Bone 431):135-139
142. Vahl TP, Drazen DL, Seeley RJ, D'Alessio DA, Woods SC2010) Meal-anticipatory glucagonlike peptide-1 secretion in rats. Endocrinology 151(2):569-575
143. Vanderhaeghen JJ, Lotstra F, De MJ, Gilles C1980) Immunohistochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. Proc Natl Acad Sci U S A 77(2):1190-1194 (Pubitemid 10101402)
144. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ2006) PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291(2):R367-R375 (Pubitemid 44035643)
145. Wang YH, Tache Y, Sheibel AB, Go VL, Wei JY1997) Two types of leptin-responsive gastric vagal afferent terminals: an in vitro single-unit study in rats. Am J Physiol 273(2 Pt 2): R833-R837 (Pubitemid 27428104)
146. Wang L, Gourcerol G, Yuan PQ, Wu SV, Million M, Larauche M et al2010) Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice. Am J Physiol Gastrointest Liver Physiol 298(1):G45-G56
147. Wang Y, Chandra R, Samsa LA, Gooch B, Fee BE, Cook JM et al2011) Amino acids stimulate cholecystokinin release through the calcium-sensing receptor. Am J Physiol Gastrointest Liver Physiol 300(4):G528-G537
148. Wank SA1995) Cholecystokinin receptors. Am J Physiol 269(5 Pt 1):G628-G646 (Pubitemid 3005920)
149. Wank SA, Pisegna JR, de Weerth A1992) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A 89(18):8691-8695
150. Weatherford SC, Laughton WB, Salabarria J, Danho W, Tilley JW, Netterville LA et al1993) CCK satiety is differentially mediated by high- and low-affinity CCK receptors in mice and rats. Am J Physiol 264(2 Pt 2):R244-R249 (Pubitemid 23085882)
151. Whitcomb DC, Taylor IL, Vigna SR1990) Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol 259(4 Pt 1):G687-G691 (Pubitemid 20340481)
152. Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125(3):549-555 (Pubitemid 28451494)
153. Wiley JW, Gross RA, MacDonald RL1993) Agonists for neuropeptide Y receptor subtypes NPY- 1 and NPY-2 have opposite actions on rat nodose neuron calcium currents. J Neurophysiol 701):324-330 (Pubitemid 23220318)
154. World Health Organisation2011) World Health Organisation report factsheet. No. 311. Obesity and Overweight
155. Wortley KE, Garcia K, Okamoto H, Thabet K, Anderson KD, Shen V et al2007) Peptide YY regulates bone turnover in rodents. Gastroenterology 133(5):1534-1543 (Pubitemid 350029744)
156. Yuan CS, Barber WD1991) Parabrachial nucleus: neuronal evoked responses to gastric vagal and greater splanchnic nerve stimulation. Brain Res Bull 27(6):797-803
157. Zarbin MA, Wamsley JK, Innis RB, Kuhar MJ1981) Cholecystokinin receptors: presence and axonal flow in the rat vagus nerve. Life Sci 29(7):697-705 (Pubitemid 12227122)
158. Zhang T, Uchida T, Gomez G, Lluis F, Thompson JC, Greeley GH Jr1993) Neural regulation of peptide YY secretion. Regul Pept 48(3):321-328
159. Zipf WB, O'Dorisio TM, Cataland S, Dixon K1983) Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. J Clin Endocrinol Metab 57(5):1074-1080 (Pubitemid 14204314)